Skip to search formSkip to main contentSkip to account menu

ProMACE-MOPP protocol

Known as: CTX/DOX/MTX/NM/PCB/PRED/VCR/VP-16, ProMACE-MOPP, ProMACE/MOPP 
A chemotherapy combination consisting of cyclophosphamide, doxorubicin, etoposide, mechlorethamine, methotrexate, prednisone, procarbazine, and… 
National Institutes of Health

Related topics

Related topics

13 relations

Broader (7)

Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamideEtoposideMechlorethamine
DoxorubicinDoxorubicin HydrochlorideMechlorethamine hydrochloridePrednisone

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
Extranodal Histiocytic Sarcoma: Clinicopathologic Analysis of 14 Cases of a Rare Epithelioid Malignancy
Histiocytic sarcoma is a rare malignant neoplasm that occurs in lymph nodes, skin, and the gastrointestinal tract. Many… 
Highly Cited
2002
Highly Cited
2002
Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients.
BACKGROUND AND OBJECTIVES This multinational retrospective study compares the outcomes of patients with primary mediastinal large… 
Highly Cited
1999
Highly Cited
1999
The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus—related systemic non‐Hodgkin lymphoma
The International Prognostic Index (IPI) effectively separates aggressive lymphomas into four groups with significantly different… 
Review
1995
Review
1995
Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment…
PURPOSE Before recognizing mantle-cell lymphoma (MCL) as a distinct entity, these patients were grouped into low-grade (LG) or… 
Highly Cited
1994
Highly Cited
1994
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National…
BACKGROUND CHOP is a four-drug, first-generation combination chemotherapy regimen that has cured approximately 30% of all… 
Highly Cited
1991
Highly Cited
1991
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
One hundred ninety-three patients with stage II, III, or IV follicular large-cell, diffuse large-cell, diffuse mixed… 
Highly Cited
1991
Highly Cited
1991
The calculation of actual or received dose intensity: a comparison of published methods.
Two recent reports of the same combination chemotherapy program, cyclophosphamide, doxorubicin, etoposide, methotrexate… 
Highly Cited
1988
Highly Cited
1988
The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
Patients with advanced indolent lymphoma often have long survival (median, 4 to 8 years) in spite of frequent relapses. The… 
Highly Cited
1984
Highly Cited
1984
Prolonged initial remission in patients with nodular mixed lymphoma.
Seventy-nine patients with nodular mixed lymphoma were treated at the National Cancer Institute between 1966 and 1978. Fifteen… 
Highly Cited
1977
Highly Cited
1977
Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)